Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE

Rhea-AI Summary

Trulieve (NYSE: TRLV) will ring The Closing Bell® at the New York Stock Exchange at 4:00 p.m. ET on August 18, 2026, to celebrate its June 10, 2026 NYSE listing. According to the company, Trulieve is the first U.S. cannabis company listed on the NYSE.

Founder and CEO Kim Rivers will lead the ceremony with the board and executive team. Trulieve reports operating 207 medical dispensaries, over 5,000 employees, and 3.5 million square feet of cultivation and production capacity across Florida, Georgia, Pennsylvania, and West Virginia, with $109 million in operating cash flow in the first half of 2026 and $325 million in cash at Q2-end.

Market Context

TRLV's recent news record included a -2.69% 24-hour reaction after its redomicile announcement. That...

Analysis

TRLV's recent news record included a -2.69% 24-hour reaction after its redomicile announcement. That context frames the NYSE ceremony as a milestone to assess alongside Net Selling insider activity, without establishing an operating result.

Key Figures

NYSE listing date: June 10, 2026 Medical dispensaries: 207 dispensaries Employees: More than 5,000 employees +5 more

8 metrics

NYSE listing date June 10, 2026 Trulieve NYSE listing

Medical dispensaries 207 dispensaries Across Florida, Georgia, Pennsylvania, and West Virginia

Employees More than 5,000 employees Company highlights

Cultivation and production capacity 3.5 million square feet Across four U.S. states

Federal rescheduling Schedule III State-licensed medical marijuana rescheduling in April 2026

Cash flow from operations $109 million First half of 2026

Cash $325 million Ending the second quarter of 2026

Texas public health regions All 11 public health regions Retail pipeline under the Texas Compassionate Use Program

Historical Context

5 past events · Latest: Aug 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	Corporate redomicile	Positive	-2.7%	Completed redomicile from British Columbia to Delaware and continued NYSE trading
Aug 07	Q2 earnings report	Negative	-2.8%	Revenue declined year-over-year while GAAP net loss included Harvest deconsolidation
Aug 05	Conference participation	Neutral	-5.1%	Announced CEO participation in Canaccord Genuity's 46th Annual Growth Conference
Jul 16	Dispensary opening	Positive	-2.5%	Announced Marco Island medical cannabis dispensary opening for July 24
Jul 10	Earnings call scheduling	Neutral	-2.5%	Scheduled second-quarter results conference call for August 7

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent non-earnings announcements were followed by negative 24-hour reactions, while the Q2 results also had a negative reaction.

Key Terms

schedule iii, dea

2 terms

schedule iii regulatory

"Following state licensed medical marijuana rescheduling to Schedule III in April 2026"

A Schedule III classification is a regulatory category for drugs and substances that have a recognized medical use but a moderate risk of dependence or abuse, placing them between higher-risk controlled drugs and over-the-counter medicines. For investors, this matters because it shapes how a product can be manufactured, prescribed, marketed and distributed — affecting potential sales, regulatory hurdles, labeling requirements and legal exposure in the market; think of it as a middle level of control that influences commercial access and compliance costs.

dea regulatory

"all 207 Trulieve medical dispensaries were registered with the U.S. Drug Enforcement"

The DEA is the U.S. Drug Enforcement Administration, the federal agency that enforces laws on controlled substances and issues licenses for handling regulated drugs. It matters to investors because DEA actions—such as granting or revoking registrations, issuing enforcement actions, or scheduling substances—can directly affect a company’s ability to manufacture, distribute, research, or sell certain pharmaceuticals, similar to how a traffic controller can speed up or stop movement on a busy road.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TALLAHASSEE, Fla., Aug. 18, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., announced it will ring The Closing Bell® at the New York Stock Exchange (NYSE) at 4:00 P.M. eastern time today, August 18, 2026, in celebration of its NYSE listing on June 10, 2026.

Founder and Chief Executive Officer Kim Rivers will be joined by members of Trulieve's Board of Directors and executive leadership team to commemorate the occasion. The bell-ringing ceremony marks a historic achievement for Trulieve as the first U.S. cannabis company listed on the NYSE and reflects the Company's leadership position in the U.S. cannabis industry.

"Ringing The Closing Bell at the New York Stock Exchange is an incredible honor and a proud moment for everyone who has contributed to Trulieve's success," said Kim Rivers, Trulieve's Chief Executive Officer. "Our NYSE listing represents the culmination of years of disciplined execution, operational excellence, and a commitment to creating long-term value for our shareholders. We are excited to celebrate this milestone alongside our team as we continue to build on our successes and capitalize on the opportunities ahead."

Company Highlights:

• Scale: Trulieve is the largest medical cannabis operator in the U.S., with 207 medical dispensaries, more than 5,000 employees, and 3.5 million square feet of cultivation and production capacity across Florida, Georgia, Pennsylvania, and West Virginia.

• Federal rescheduling: Following state licensed medical marijuana rescheduling to Schedule III in April 2026, all 207 Trulieve medical dispensaries were registered with the U.S. Drug Enforcement Administration (DEA), with inspections completed in Florida, Pennsylvania, and West Virginia.

• Georgia: Medical marijuana program expansion under SB 220 accelerated patient enrollment and enabled the launch of new Modern Flower and Roll One branded vape and inhalable flower products across retail dispensaries and independent pharmacies.

• Texas: Trulieve has initial production capacity ready for final inspection and retail pipeline spanning all 11 public health regions to serve patients under the Texas Compassionate Use Program (TCUP) upon receipt of final licensure.

• Financial Strength: Trulieve generated $109 million in cash flow from operations in the first half of 2026, ending the second quarter with $325 million in cash.

A video of the bell-ringing ceremony will be available for viewing on the NYSE's website at www.nyse.com/bell.

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia. Driven by a core mission to expand access to cannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaled operations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth. Trulieve is listed on the NYSE under the symbol TRLV. For more information, please visit Trulieve.com.

Facebook: @Trulieve   Instagram: @Trulieve   X: @Trulieve

Investor and Media Contact
Christine Hersey, Chief Corporate Affairs and Strategy Officer
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-to-ring-the-closing-bell-at-the-new-york-stock-exchange-as-first-us-cannabis-company-listed-on-the-nyse-302853436.html

SOURCE Trulieve Cannabis Corp.

FAQ

Why is Trulieve (NYSE: TRLV) ringing the NYSE Closing Bell on August 18, 2026?

Trulieve is ringing the NYSE Closing Bell to celebrate its NYSE listing on June 10, 2026. According to Trulieve, this ceremony marks its status as the first U.S. cannabis company listed on the NYSE and recognizes its leadership in the U.S. medical cannabis industry.

When did Trulieve (TRLV) become the first U.S. cannabis company listed on the NYSE?

Trulieve’s shares began trading on the New York Stock Exchange on June 10, 2026. According to Trulieve, this listing made it the first U.S. cannabis company on the NYSE and is described as the culmination of years of disciplined execution and operational focus.

What is the scale of Trulieve’s operations mentioned in the August 18, 2026 NYSE bell announcement?

Trulieve reports operating 207 medical dispensaries and employing more than 5,000 people. According to Trulieve, it also has 3.5 million square feet of cultivation and production capacity across Florida, Georgia, Pennsylvania, and West Virginia, positioning it as a large U.S. medical cannabis operator.

What financial metrics did Trulieve (NYSE: TRLV) highlight around its NYSE bell ringing in August 2026?

Trulieve highlighted generating $109 million in cash flow from operations in the first half of 2026. According to Trulieve, the company ended the second quarter of 2026 with $325 million in cash, underscoring available liquidity to support its medical cannabis operations and expansion plans.

How did federal rescheduling affect Trulieve’s medical cannabis dispensaries in 2026?

Following state licensed medical marijuana rescheduling to Schedule III in April 2026, all 207 Trulieve medical dispensaries were registered with the DEA. According to Trulieve, inspections have been completed in Florida, Pennsylvania, and West Virginia, reflecting regulatory alignment for its existing medical cannabis footprint.

What growth initiatives did Trulieve (TRLV) describe in Georgia and Texas in its NYSE bell announcement?

In Georgia, Trulieve cited program expansion under SB 220 and new Modern Flower and Roll One products. According to Trulieve, it also has initial production capacity and a retail pipeline ready in Texas under the Compassionate Use Program, pending final licensure and inspection.